Perenteral Nutrition and Oxidative Stress in Preterm Infants
Study of the Oxidant-Antioxidant Effects of Parenteral Nutrition in Preterm Neonates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Preterm infants included are:
- with gestational age between 28 to 34 weeks
- managed with TPN as part of their care in the NICU
- their postnatal age on enrolment was < 7 days
Exclusion Criteria:
Infants are excluded if they have:
- Clinical evidence of sepsis, or a positive blood culture on admission
- Hepatobiliary dysfunction
- Persistent metabolic acidosis with base deficit > 10 mEq / L
- Renal impairment (urine output < 1 ml/kg/hour and serum creatinine > 1 mg/dl)
- Disseminated intravascular coagulopathy
- Maternal conditions known to be associated with oxidative stress such as preeclampsia, hypertension and diabetes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 1
Perenteral nutrition bottle and tubing are not protected from light
|
Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
|
|
Active Comparator: 2
Perenteral nutrition bottle and tubing are protected from light
|
Parenteral solutions are protected from day light using aluminum covers
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Concentration of peroxides in the urine
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical morbidities (death, and bronchopulmonary dysplasia)
Time Frame: during hospital stay
|
during hospital stay
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Mohamed R Bassiouny, MD, Mansoura University Children's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2003-MD-thesis-nehad
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.